JPWO2021188729A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021188729A5 JPWO2021188729A5 JP2022556229A JP2022556229A JPWO2021188729A5 JP WO2021188729 A5 JPWO2021188729 A5 JP WO2021188729A5 JP 2022556229 A JP2022556229 A JP 2022556229A JP 2022556229 A JP2022556229 A JP 2022556229A JP WO2021188729 A5 JPWO2021188729 A5 JP WO2021188729A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- grna
- protein
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991403P | 2020-03-18 | 2020-03-18 | |
| US62/991,403 | 2020-03-18 | ||
| PCT/US2021/022840 WO2021188729A1 (en) | 2020-03-18 | 2021-03-17 | Compositions and methods for the targeting of c9orf72 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023518541A JP2023518541A (ja) | 2023-05-02 |
| JP2023518541A5 JP2023518541A5 (https=) | 2024-03-28 |
| JPWO2021188729A5 true JPWO2021188729A5 (https=) | 2024-03-28 |
| JP7847853B2 JP7847853B2 (ja) | 2026-04-20 |
Family
ID=75478206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556229A Active JP7847853B2 (ja) | 2020-03-18 | 2021-03-17 | Ｃ９ｏｒｆ７２の標的化のための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240309344A1 (https=) |
| EP (1) | EP4121535A1 (https=) |
| JP (1) | JP7847853B2 (https=) |
| KR (1) | KR20230002401A (https=) |
| CN (1) | CN116096885A (https=) |
| AU (1) | AU2021237633A1 (https=) |
| BR (1) | BR112022018673A2 (https=) |
| CA (1) | CA3172178A1 (https=) |
| CO (1) | CO2022014598A2 (https=) |
| IL (1) | IL296477A (https=) |
| MX (1) | MX2022011460A (https=) |
| WO (1) | WO2021188729A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| EP4288541A1 (en) | 2021-02-05 | 2023-12-13 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| EP4423263A4 (en) * | 2021-10-29 | 2026-03-04 | Mammoth Biosciences Inc | EFFECTOR PROTEINS, COMPOSITIONS, SYSTEMS, DEVICES, KITS AND METHODS FOR THERECOMMENDATION |
| US20250011766A1 (en) * | 2021-11-09 | 2025-01-09 | Prime Medicine, Inc. | Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis |
| WO2023235725A2 (en) * | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240157A2 (en) * | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
| US20250361525A1 (en) * | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2024173479A2 (en) * | 2023-02-15 | 2024-08-22 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2025024285A1 (en) * | 2023-07-21 | 2025-01-30 | Mammoth Biosciences, Inc. | Compositions for the modification of the human c9orf72 gene |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| WO2012068627A1 (en) | 2010-11-24 | 2012-05-31 | The University Of Western Australia | Peptides for the specific binding of rna targets |
| WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| BR112018012894A2 (en) * | 2015-12-23 | 2018-12-04 | Crispr Therapeutics Ag | Materials and Methods for Treatment of Amyotrophic Lateral Sclerosis and / or Frontotemporal Lobular Degeneration |
| CA3038960A1 (en) * | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
| WO2018208972A1 (en) * | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
| WO2019030306A1 (en) * | 2017-08-08 | 2019-02-14 | Depixus | ISOLATION AND IN VITRO ENRICHMENT OF NUCLEIC ACIDS USING SITE-SPECIFIC NUCLEASES |
| US11578334B2 (en) * | 2017-10-25 | 2023-02-14 | Monsanto Technology Llc | Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes |
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
-
2021
- 2021-03-17 BR BR112022018673A patent/BR112022018673A2/pt unknown
- 2021-03-17 EP EP21718316.9A patent/EP4121535A1/en active Pending
- 2021-03-17 AU AU2021237633A patent/AU2021237633A1/en active Pending
- 2021-03-17 JP JP2022556229A patent/JP7847853B2/ja active Active
- 2021-03-17 CA CA3172178A patent/CA3172178A1/en active Pending
- 2021-03-17 KR KR1020227035510A patent/KR20230002401A/ko active Pending
- 2021-03-17 WO PCT/US2021/022840 patent/WO2021188729A1/en not_active Ceased
- 2021-03-17 MX MX2022011460A patent/MX2022011460A/es unknown
- 2021-03-17 IL IL296477A patent/IL296477A/en unknown
- 2021-03-17 CN CN202180034169.7A patent/CN116096885A/zh active Pending
-
2022
- 2022-09-16 US US17/932,798 patent/US20240309344A1/en active Pending
- 2022-10-14 CO CONC2022/0014598A patent/CO2022014598A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021188729A5 (https=) | ||
| JP7832262B2 (ja) | 肝特異的ウイルスプロモーター及びその使用方法 | |
| US12529051B2 (en) | Methods of treating amyotrophic lateral sclerosis (ALS) | |
| JP2024028643A5 (https=) | ||
| JP2025028917A (ja) | 核酸構築物及び使用方法 | |
| US20230121437A1 (en) | Rna editor-enhanced rna trans-splicing | |
| JP2022173348A (ja) | 高活性制御エレメント | |
| CA3097857A1 (en) | Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna | |
| WO2020214609A1 (en) | Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy | |
| JPWO2020247882A5 (https=) | ||
| US20230201375A1 (en) | Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1) | |
| EP3294891B1 (en) | Polynucleotides, vectors and methods for insertion and expression of transgenes | |
| US20240026381A1 (en) | Split prime editing platforms | |
| CN116949012B (zh) | 一种融合蛋白及其应用 | |
| CA3218209A1 (en) | Multiplex crispr/cas9-mediated target gene activation system | |
| WO2024120528A1 (en) | Improved system for producing rna-packaged aav particles | |
| WO2024078645A2 (zh) | Cas蛋白及其应用 | |
| CN115947796B (zh) | 一种重组腺相关病毒载体及其在基因递送中的应用 | |
| JPWO2022120094A5 (https=) | ||
| WO2024050547A2 (en) | Compact bidirectional promoters for gene expression | |
| WO2023147558A2 (en) | Crispr methods for correcting bag3 gene mutations in vivo | |
| CA3218631A1 (en) | Vector system | |
| KR102640462B1 (ko) | 신경병증성 통증의 치료를 위한 방법 및 조성물 | |
| US20240415984A1 (en) | Precise Excisions of Portions of Exons for Treatment of Duchenne Muscular Dystrophy | |
| US20250135032A1 (en) | Crispr methods for correcting bag3 gene mutations in vivo |